Theravance Biopharma (TBPH) investor relations material

Executive summary

• Report covers the quarter ended March 31, 2026, focusing on YUPELRI commercialization, the wind-down of the ampreloxetine program after negative Phase 3 results, and organizational restructuring to reduce costs.

• Strategic Review Committee is evaluating alternatives, including a potential sale, to maximize shareholder value.

• Organizational restructuring targets a 60% reduction in operating expenses by Q3 2026, impacting about 50% of the workforce and reducing G&A staff by 50%.

• Quarter-end cash balance was $394.7 million with no long-term debt.

• All Hatch-Waxman litigation for YUPELRI resolved after a settlement with Mankind Pharma, allowing generic entry after April 23, 2039.

Financial highlights

• Q1 2026 revenue was $17.7 million, up 15% year-over-year, driven by YUPELRI collaboration with Viatris.

• Net loss for Q1 2026 was $4.9 million, improved from $13.6 million in Q1 2025.

• Operating expenses decreased 9% year-over-year to $27.2 million, with restructuring expenses of $3.6 million.

• Cash, cash equivalents, and marketable securities totaled $394.7 million as of March 31, 2026.

• Received $25 million milestone from Viatris and $50 million milestone from Royalty Pharma in Q1 2026.

Outlook and guidance

• Full run-rate cost savings of approximately $70 million expected to be realized beginning in Q3 2026.

• On track to reduce operating expenses by 60%, with $60–$70 million of annualized cash flow expected starting Q3 2026.

• Cash resources are expected to fund operations for at least the next twelve months based on current plans.

• Strategic review process ongoing; no assurance of transaction outcome.

• Expects $5–$7 million in one-time cash severance costs related to restructuring.